Rho-kinase inhibitors
Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
1 . A compound of formula I
wherein R 1 and R 2 are each independently
furyl, thienyl, pyridyl, trifluoromethyl or phenyl each optionally substituted with NH 2 , NO 2 trifluoromethyl or alkoxy; or
R 1 and R 2 may be taken together to form a ring of from 5 to 7 members optionally interrupted by N and optionally substituted on N by benzyl;
R 3 is NH 2 or —NH— phenyl, phenyl substituted with halo, C 1 -C 4 alkyl, trifluoromethyl, nitro or amino;
R 4 is
or indol-5-yl (optionally) substituted on N with pyridyl;
X is a linker substituted at the 3 or 4 position of the ring and is O, S, —S—CH 2 —, —CH 2 ) m —, or —(C═O)—;
A is phenyl, phenyl substituted with alkylthio or OH,
pyridyl,
quinolyl or
isoquinolyl;
each R 5 independently is halo, alkyl optionally substituted by halo up to perhalo, cycloalkyl, alkoxy, alkenyl, alkynyl, NO 2 , NH 2 , or trifluoromethyl;
n is 0, 1, 2, 3 or 4;
m is 1 or 2; and
R 6 and R 7 are each independently H, alkyl, or phenyl optionally substituted with halo, CF 3 , alkyl, nitro or amino; or
R 6 and R 7 may form, together with the N atom to which they are attached, a heterocyclic ring optionally substituted with alkyl, optionally interrupted by O, or optionally fused to phenyl;
or a pharmaceutically acceptable salt thereof,
with the proviso that formula I does not include the following compounds:
2 . A compound of formula I according to claim 1 , wherein
R 1 and R 2 are each independently H, halo, C 1-12 alkyl optionally substituted by halo up to perhalo, C 2-12 , alkenyl, C 2-12 -alkynyl, NO 2 , NH 2 , NR 6 R 7 , alkyl, furyl, thienyl, pyridyl, phenyl optionally substituted with NO 2 , trifluoromethyl or NR 6 R 7 ; or
R 1 and R 2 together form a ring of from 5 to 7 members optionally interrupted by N and optionally substituted on N by benzyl;
R 3 is NH 2 or —NH— phenyl optionally substituted with halo, C 1 -C 4 alkyl, trifluoromethyl, nitro or amino;
R 4 is
or indol-5-yl (optionally) substituted on the N with pyridyl;
X is a linker substituted at the 3 or 4 position of the ring and is selected from O, S, —S—CH 2 —, —CH 2 —S—, —(CH 2 ) m —, or —C═O)—;
A is phenyl optionally substituted by C 1-4 alkylthio or OH,
pyridyl,
quinolyl or
isoquinolyl;
each R 5 independently is halo, C 1 -C 12 alkyl, optionally substituted by halo, up to the perhalo level, C 2-12 -alkenyl, C 2-12 -alkynyl, NO 2 , NH 2 or trifluoromethyl;
n is 0, 1, 2, 3 or 4;
m is 1 or 2; and
R 6 and R 7 are each independently H, C 1 -C 6 alkyl, or phenyl optionally substituted with halo, CF 3 , Cl —C 4 alkyl, nitro or amino.
3 . A compound according to claim 1 , wherein X is not S or A is not pyridyl.
4 . A compound according to claim 1 , wherein X is not S or —S—CH 2 .
5 . A compound according to claim 1 , wherein n is 1-4.
6 . A compound according to claim 1 , wherein n is 1-4 and each R 5 is independently is halo, C 3 -C 12 alkyl optionally substituted by halo up to the perhalo level, C 2-12 -alkenyl, C 2-12 -alkynyl, NO 2 , NH 2 or trifluoromethyl.
7 . A compound according to claim 1 , which is 4-({4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl}sulfanyl)phenol, N-(2-amino-6-methyl-4-pyrimidinyl)-N-[4-(3-pyridinylsulfanyl)phenyl]amine, N-(2-amino-6-methyl-4-pyrimidinyl)-N-[3-(4-pyridinylsulfanyl)phenyl]amine, N-(2-anilino-6-methyl-4-pyrimidinyl)-N-[4-(4-pyridinylsulfanyl)phenyl]amine, N, (2-amino-6-methyl-4-pyrimidinyl)-N-[4-(5-quinolinyloxy)phenyl]amine, N-(2-amino-6-phenyl-4-pyrimidinyl)-N-[3,5-dichloro-4-(4-pyridinylsulfanyl)phenyl]amine, N-[2-amino-6-(3-nitrophenyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine, N-[2-amino-6-(2-furyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine, N-[2-amino-6-(2-thienyl)-4-pyrimidinyl]-N-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]amine, N-[2-amino-6-ethoxyphenyl)-4-pyrimidinyl]-N-[3-fluoro-4(4-pyridinylsulfanyl)phenyl]amine.
8 . A compound according to claim 1 , of the formula
9 . A compound according to claim 1 , of the formula
10 . A compound according to claim 1 , of the formula
11 . A method of treating an indication mediated by Rho-kinase, comprising administering a compound of claim 1 .
12 . A method of treating hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancer of the breast, colon, prostate, ovaries, brain or lung, thrombotic disorders, asthma, glaucoma, osteoporosis or erectile dysfunction, comprising administering to host in need thereof a compound according to claim 1 .
13 . A process according to claim 11 , wherein the host is a human.
14 . A process according to claim 12 , wherein the host is a human.
15 . A process for the preparation of a compound of claim 1 , comprising reacting
and optionally, where R 1 is NR 6 R 7 , reacting the chloropyrimidine of Formula Ia with an amine of Formula R 6 R 7 NH.
16 . A method of treating atherosclerosis, comprising administering a compound of claim 1 .
17 . A method of treating hypertension, comprising administering a compound of claim 1.